Pathophysiological role of microRNA-29 in pancreatic cancer stroma

Jason J. Kwon, Sarah C. Nabinger, Zachary Vega, Smiti Snigdha Sahu, Ravi K. Alluri, Zahi Abdul-Sater, Zhangsheng Yu, Jesse Gore, Grzegorz Nalepa, Romil Saxena, Murray Korc, Janaiah Kota

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Dense fibrotic stroma associated with pancreatic ductal adenocarcinoma (PDAC) is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Current, anti-stromal therapies have failed to improve tumor response to chemotherapy and patient survival. Furthermore, recent studies show that stroma impedes tumor progression, and its complete ablation accelerates PDAC progression. In an effort to understand the molecular mechanisms associated with tumor-stromal interactions, using in vitro and in vivo models and PDAC patient biopsies, we show that the loss of miR-29 is a common phenomenon of activated pancreatic stellate cells (PSCs)/fibroblasts, the major stromal cells responsible for fibrotic stromal reaction. Loss of miR-29 is correlated with a significant increase in extracellular matrix (ECM) deposition, a major component in PDAC stroma. Our in vitro miR-29 gain/loss-of-function studies document the role of miR-29 in PSC-mediated ECM stromal protein accumulation. Overexpression of miR-29 in activated stellate cells reduced stromal deposition, cancer cell viability, and cancer growth in co-culture. Furthermore, the loss of miR-29 in TGF-β1 activated PSCs is SMAD3 dependent. These results provide insights into the mechanistic role of miR-29 in PDAC stroma and its potential use as a therapeutic agent to target PDAC.

Original languageEnglish (US)
Article number11450
JournalScientific reports
StatePublished - Jun 22 2015

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Pathophysiological role of microRNA-29 in pancreatic cancer stroma'. Together they form a unique fingerprint.

Cite this